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Cervical intraepithelial neoplasia 
disease progression is associated 
with increased vaginal microbiome 
diversity
A. Mitra1,2, D. A. MacIntyre1, Y. S. Lee1, A. Smith3, J. R. Marchesi3,4, B. Lehne5, R. Bhatia6, 
D. Lyons7, E. Paraskevaidis8, J. V. Li4, E. Holmes4, J. K. Nicholson4, P. R. Bennett1,2 & 
M. Kyrgiou1,2
Persistent infection with oncogenic Human Papillomavirus (HPV) is necessary for cervical 
carcinogenesis. Although evidence suggests that the vaginal microbiome plays a functional role 
in the persistence or regression of HPV infections, this has yet to be described in women with 
cervical intra-epithelial neoplasia (CIN). We hypothesised that increasing microbiome diversity is 
associated with increasing CIN severity. llumina MiSeq sequencing of 16S rRNA gene amplicons was 
used to characterise the vaginal microbiota of women with low-grade squamous intra-epithelial 
lesions (LSIL; n = 52), high-grade (HSIL; n = 92), invasive cervical cancer (ICC; n = 5) and healthy 
controls (n = 20). Hierarchical clustering analysis revealed an increased prevalence of microbiomes 
characterised by high-diversity and low levels of Lactobacillus spp. (community state type-CST IV) 
with increasing disease severity, irrespective of HPV status (Normal = 2/20,10%; LSIL = 11/52,21%; 
HSIL = 25/92,27%; ICC = 2/5,40%). Increasing disease severity was associated with decreasing relative 
abundance of Lactobacillus spp. The vaginal microbiome in HSIL was characterised by higher levels 
of Sneathia sanguinegens (P < 0.01), Anaerococcus tetradius (P < 0.05) and Peptostreptococcus 
anaerobius (P < 0.05) and lower levels of Lactobacillus jensenii (P < 0.01) compared to LSIL. Our 
results suggest advancing CIN disease severity is associated with increasing vaginal microbiota 
diversity and may be involved in regulating viral persistence and disease progression.
Persistent infection with a high-risk oncogenic Human Papillomavirus (HPV) subtypes, most commonly 
16 and 18, is a necessary, although not sufficient, condition for development of invasive cervical cancer 
(ICC) and its precancerous precursor; cervical intra-epithelial neoplasia (CIN)1. Although HPV infec-
tion is very common in sexually-active women2, the majority of infections are transient3. Only a small 
proportion of women infected with the virus goes on to develop clinically significant pre-invasive lesions 
and, if not treated, invasive malignant disease. Mechanisms of persistence of HPV infection are not well 
understood.
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The vaginal microenvironment plays an important role in reproductive health. Commensal vaginal 
Lactobacillus spp. are thought to defend against pathogens and sexually transmitted infections4 through 
maintenance of a hostile pH5, production of species-specific metabolites, bacteriocins and through 
adherence to mucous and disruption of biofilms6–9. Next generation sequencing (NGS) based studies 
have facilitated detailed characterisation of the “healthy” vaginal microbiome and shown that 5 major 
community-state types (CSTs) exist; CST I, II, III and V are dominated by Lactobacillus crispatus, L. 
gasseri, L. iners and L. jensenii respectively, whereas CST IV has characteristically low numbers of 
Lactobacillus spp. and increased diversity of anaerobic bacteria10. Longitudinal studies of the vaginal 
microbiome using NGS indicates that bacterial community structure is dynamic and hormonally influ-
enced with a propensity to become less stable during menstruation11 and conversely more stable and less 
diverse during normal pregnancy12,13. The stability and composition of the vaginal microbiome may play 
an important role in determining host innate immune response and susceptibility to infection. Bacterial 
vaginosis (BV), a condition characterised by Lactobacillus spp. depletion, overgrowth of anaerobic spe-
cies, and higher vaginal pH has been associated with increased transmission rates of sexually-transmitted 
infections14 and human immunodeficiency virus (HIV)15. Conversely, it has recently been reported that 
viral infection of the cervix during murine pregnancy increases susceptibility of ascending vaginal bac-
terial infection through sensitisation and priming of the host innate immune system16.
Relatively little is known about the mechanisms associated with clearance or persistence of HPV 
infection. Along with higher rates of HPV infection, BV has been associated with delayed clearance 
of the virus and with CIN, suggesting that a diverse, Lactobacillus-depleted microbiome may play a 
mechanistic role17–20. A recent study of 68 HPV-discordant monozygotic female Korean twins using 
NGS showed that HPV-positive twins had lower levels of Lactobacillus spp. and increased counts of 
Fusobacteria and Sneathia spp. compared to their HPV-negative twins21. Consistent with these findings, 
analysis of vaginal swabs collected longitudinally for 16 weeks from 32 sexually active women found that 
a Lactobacillus spp.-depleted, Atopobium spp. enriched (CST IV) community structure is associated with 
slowest regression of HPV whereas a Lactobacillus gasseri-dominated microbiome (CST II) is associated 
with the most rapid regression rates for HPV22.
While there is evidence of an association between vaginal microbiome structure and HPV infection, 
the potential relationship between the vaginal microbiota and CIN disease progression has yet to be 
investigated. In this study, we characterised the vaginal microbiome structure and diversity in women 
with pre-invasive cervical intraepithelial neoplasia, invasive cervical cancer, and in healthy controls to 
assess how CSTs may correlate with disease presence and severity. We hypothesised that increasing 
microbiome diversity is associated with increasing CIN severity.
Results
We enrolled 169 women into the study who were classified into 4 groups; normal (n = 20), low-grade 
squamous intraepithelial lesion (LSIL) (n = 52), high-grade squamous intraepithelial lesion (HSIL) (n = 92) 
and ICC (n = 5). Table 1 shows the characteristics of each group. No difference in the mean age of the pop-
ulation was determined (mean 31, SD 5.08, range 23–45, P = 0.071). No category showed systematic bias 
with respect to the four disease-groups after adjustment for multiple hypothesis testing. There was equal 
distribution in the samples collected at the follicular or luteal phase of the cycle and in the rate of women 
that had intercourse within 48 hours from sample collection. Histology was available in all HSIL and cancer 
cases (100%), and for 69% (36/52) and 5% (1/20) of LSIL and normal cases, respectively.
The structure of the vaginal microbiome correlated to the disease severity. In total 8 409 192 
reads were obtained from 169 samples with an average number of reads per sample of 49 759 and the 
mean and median read lengths of 513 and 520 bp respectively. To avoid sequencing bias, operational taxo-
nomic units (OTUs) were randomly sub-sampled to the lowest read count of 183, which retained 97% of 
OTU counts (data not shown) and still provided coverage of > 96% for all samples. Following removal of 
singletons and rare OTUs, a total of 49 taxa were identified in the vaginal microbiome of the study cohort.
Initial assessment of vaginal community structure was performed using principal component analysis 
(PCA) of species sequence data in the context of disease grade (normal, LSIL, HSIL and ICC) (Fig. 1). 
Three major clusters were identified which represented samples dominated by either L. crispatus, L. iners 
or samples depleted of Lactobacillus spp. with higher diversity. The results of the analysis at class level are 
presented in Supplementary Figure 1.
Hierarchical clustering analysis (HCA) of the sequence data using nearest neighbour linkage at spe-
cies level (Fig. 2) identified 5 major clusters that exhibited bacterial community structure consistent with 
previously described vaginal microbiome community state types (CSTs); CST I: L. crispatus-dominated, 
CST II: L. gasseri-dominated, CST III: L. iners-dominated, CST IV: Lactobacillus-depleted and CST V: 
L. jensenii-dominated10 (Fig. 2). The results of the analysis at class level are presented in Supplementary 
Figure 2 & Supplementary Table 1.
The rates and frequency of the different CSTs (I, II, III, IV & V) were compared between CIN disease 
severities and healthy controls (Table 2; Supplementary Table 3; Fig. 2). CST I was the most frequent CST 
in our study cohort (70/169, 41% of all patients), followed by CST III (47/169, 28%), CST IV (40/169, 
24%), CST V (7/169, 4%) and CST II (5/169, 3%). Higher rates of CST IV (Lactobacillus-depleted, high 
diversity) were associated with increasing disease severity with CST IV observed twice as frequently in 
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women with LSIL, three times as frequently in women with HSIL and four times as frequently in women 
with ICC when compared to disease free controls (normal = 2/20, 10%; LSIL = 11/52, 21%; HSIL = 25/92, 
27%; cancer = 2/5, 40%). Conversely, frequency of CST I (Lactobacillus crispatus-dominant) was lower 
with increasing disease severity (normal = 10/20, 50%; LSIL = 22/52, 42%; HSIL = 37/92, 40%; can-
cer = 1/5, 20%). The number of ICC cases was small for any valid conclusion. Although the results of 
the analysis did not attain significance given the modest sample size, there appears to be a correlation of 
CST IV and increasing disease severity.
A similar distribution of CST IV was observed when women with HPV/Atypical squamous cells 
of undetermined significance (ASCUS) and LSIL changes were analysed as two separate groups (nor-
mal = 2/20, 10%; ASCUS = 5/26, 19%; LSIL = 6/26, 23%; HSIL = 25/92, 27%; cancer = 2/5, 40%) (Table 2; 
Fig. 2; Supplementary Table 3). These analyses are suggestive of association between CST IV and increas-
ing disease severity, and are consistent with the expected direction of effect, but do not attain significance 
due to modest sample-size.
Both species richness (Fig. 3A) and alpha-diversity (Fig. 3B,C) indices were higher in CST IV, com-
pared to the other CSTs particularly CST I (P < 0.001) and CST III (P < 0.01) (Fig. 3). Consistent with 
increased rates of CST IV in high grade disease, vaginal microbiota richness and diversity were also 
Characteristics
Normal 
(n = 20) LSIL (n = 52)
HSIL 
(n = 92)
Cancer 
(n = 5) Total (n = 169) P value
Q 
value
Age, years
Mean (SD, range) 31 (5.19, 24–43)
32 (5.66, 
23–45)
30 (4.65, 
25–43)
34 (5.29, 
27–41) 31 (5.08, 23–45)
Ethnicity , n/N (%) 0.04 0.20
Caucasian 12/20 (60) 46/52 (88) 78/92 (85) 4/5 (80) 140/169 (83)
Asian 2/20 (10) 3/52 (6) 9/92 (10) 0/5 (0) 14/169 (8)
Black 6/20 (30) 3/52 (6) 5/92 (5) 1/5 (20) 15/169 (9)
Parity, n/N (%) 0.83 1.00
Nulliparous 16/20 (80) 38/52 (73) 68/92 (74) 3/5 (60) 125/169 (74)
Parous 4/20 (20) 14/52 (27) 24/92 (26) 2/5 (40) 44/169 (26)
Smoking status, n/N (%) 0.07 0.37
Current smoker 1/20 (5) 11/52 (21) 28/92 (30) 1/5 (20) 41/169 (24)
Non-smoker 19/20 (95) 41/52 (79) 64/92 (70) 4/5 (80) 128/169 (76)
Phase of menstrual cycle, 
n/N (%) 0.13 0.52
Luteal 7/20 (35) 27/52 (52) 42/92 (46) 5/5 (100) 81/169 (48)
Follicular 11/20 (55) 21/52 (40) 47/92 (51) 0/5 (0) 79/169 (47)
Unknown 2/20 (10) 3/52 (8) 3/92 (3) 0/5 (0) 8/169 (5)
Contraception, n/N (%) 0.02 0.12
Nil 15/20 (75) 18/52 (35) 29/92 (32) 1/5 (20) 63/169 (37)
Condoms 1/20 (5) 10/52 (19) 16/92 (17) 0/5 (0) 27/169 (16)
COCP 3/20 (15) 11/52 (21) 35/92 (38) 2/5 (40) 51/169 (30)
POP 0/20 (0) 4/52 (8) 4/92 (4) 0/5 (0) 8/169 (5)
Copper IUD 0/20 (0) 2/52 (4) 2/92 (2) 1/5 (20) 5/169 (3)
Mirena IUS 1/20 (5) 1/52 (2) 3/92 (3) 1/5 (20) 6/169 (4)
Vaginal Ring 0/20 (0) 0/52 (0) 2/92 (2) 0/5 (0) 2/169 (1)
Contraceptive implant 0/20 (0) 4/52 (8) 1/92 (1) 0/5 (0) 5/169 (3)
Contraceptive injection 0/20 (0) 2/52 (4) 0/92 (0) 0/5 (0) 2/169 (1)
Time since last intercourse, 
n/N (%) 0.20 0.60
> 48 hours 16/20 (80) 49/52 (94) 77/92 (84) 5/5 (100) 147/169 (87)
< 48 hours 4/20 (20) 3/52 (6) 14/92 (16) 0/5 (0) 21/169 (13)
Table 1.  Patient characteristics. COCP: Combined oral contraceptive pill; HSIL: High-grade Squamous 
intraepithelial lesion; IUD: Intrauterine device; IUS: Intrauterine system; LSIL: Low-grade squamous 
intraepithelial lesion; NR: not relevant; POP: Progesterone-only pill; SD: standard deviation. P-value 
calculated using Fishers exact test, Q-value calculated using Benjamini-Hochberg false discovery rate (FDR) 
method.
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found to be higher in women with high-grade disease, compared to low-grade disease, and lowest in 
normal women but this was not statistically significant (Fig. 4) (Supplementary Table 4).
The structure of the vaginal microbiome correlated to the HPV status and genotype. HPV 
status was available for 117 women in our cohort. CST IV was most frequently observed in high-risk 
HPV (HR-HPV) positive as compared to HR-HPV negative women (26/93, 28% versus 5/24, 21%). HPV 
negative women were most likely to have CST I (13/24, 54%) as opposed to HPV positive women (38/93, 
41%). The rates for the other CSTs were comparable between HR-HPV positive and negative subjects 
(Table 2; Fig. 2).
Of 93 women who were HPV positive, genotyping was available for 62 subjects. The rate of CST 
IV was higher for women infected with HPV16 (9/31, 29%) when compared to HPV18 (1/5, 20%) or 
women with other high-risk oncogenic types (5/26, 19%) although did not reach significance, likely due 
to sample size (Table 2; Fig. 2).
The rate of CST IV was no different for Normal/LSIL HPV negative versus HPV positive individuals 
(3/20, 15% versus 7/34, 21%), but substantially higher for HSIL or worse (HSIL = 19/58, 33%; ICC = 2/5, 
40%), suggesting that the presence of a high diversity Lactobacillus-depleted microbiome may be more 
strongly correlated to the presence of clinically significant pre- or invasive disease rather than the pres-
ence of the virus itself (Table 2; Supplementary Table 3; Fig. 2). Again, the results did not reach statistical 
significance.
Identification of vaginal microbiota composition markers of CIN disease severity. Linear dis-
criminant analysis (LDA) effect size (LEfSe) modeling was used to identify differences in microbiota 
composition that may be related to increasing disease severity (Fig. 5). Due to sample size restrictions, we 
limited our comparison to LSIL versus HSIL patients. In the LSIL group, significant over-representation 
of Lactobacillus jensenii (P < 0.01) (Fig. 5A,B,F) and Lactobacillus coleohominis (P < 0.05) (Fig. 5B) were 
observed. In contrast, HSIL samples were found to have significantly higher levels of Peptostreptococcus 
anaerobius (P < 0.05), and Anaerococcus tetradius (P < 0.05) (Fig.  5A–D). HSIL samples were also 
found to have significant overrepresentation of Fusobacteria- primarily Sneathia sanguinegens (P < 0.01) 
(Fig. 5A,B,E; Supplementary Figure 3).
Figure 1. Bacterial species diversity in study cohort and controls. Principle component analysis (PCA) 
of vaginal bacterial species data identified 3 major clusters corresponding to samples dominated by three 
community state types (CSTs): L. iners (CST III), L. crispatus (CST I) and high diversity samples (CST IV). 
KEY - Cancer: Black; High-grade squamous intra-epithelial lesions (HSIL): Red; Low-grade squamous intra-
epithelial lesions (LSIL): Yellow; Normal: Green.
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Discussion
We detected a two-fold increase in the rate of a CST IV vaginal microbiome in those women with LSIL, 
a three-fold increase in women with HSIL and a four-fold increase in women with invasive cancer com-
pared to controls. Increasing disease severity was also associated with decreasing relative abundance of 
Lactobacillus spp. A recent longitudinal study by Brotman et al. reported that women with a high diver-
sity, Lactobacillus spp. depleted (CST IV) vaginal microbiome were most likely to become HPV-positive, 
and to have persistent HPV infection22. Our findings suggest that vaginal microbial diversity is associated 
not only with HPV infection, but also with advancing CIN severity, but does not attain significance due 
to modest sample-size.
It is currently unclear if a CST IV microbiome is a causal factor in progression of CIN or a consequence 
of it. BV, a condition diagnosed using traditional culture techniques, in part by Lactobacillus spp. depletion 
and increased diversity of potentially pathogenic gram negative bacteria, is associated with significantly 
higher rates of HPV infection and CIN19,20. We used NGS techniques to further examine this association 
Figure 2. Vaginal microbiome composition according to disease and HPV status. Hierarchical clustering 
analysis (HCA) using centroid clustering showed the distribution of CSTs differs in healthy, normal control 
women (green), compared to those with disease (Disease Severity I). Frequency of CST IV was 2-fold greater 
in women with LSIL (yellow), 3-fold greater in HSIL (red) and 4-fold greater in women with ICC (black), 
compared to controls, with a reciprocal decrease in frequency of CST I with increasing disease severity. 
When HPV/ASCUS (light grey) and LSIL (dark grey) were examined as two separate groups, the stepwise 
increase in CST IV prevalence was maintained (Disease Severity II). HPV positivity (blue) was associated 
with increased rates of CST IV, compared to HPV negative women (light grey) who were most likely to 
have CST I (HPV status). HPV-16 (pink) was most frequently associated with CST IV (HPV genotype). 
Rates of CST IV were similar in women with normal or LSIL regardless of HPV status (negative = light 
grey, positive = dark grey), and were substantially higher in women with HSIL and positive for HPV (blue) 
(Disease severity I & HPV status). DISEASE SEVERITY I - Normal: Green; Low-grade squamous intra-
epithelial lesions (LSIL): Yellow; High-grade squamous intra-epithelial lesions (HSIL): Red; Cancer: Black. 
DISEASE SEVERITY II - Normal: white; ASCUS: light grey; LSIL: dark grey; HSIL: blue; Cancer: pink. 
HPV STATUS - HPV negative: light grey; HPV positive: blue; Unknown: white. HPV GENOTYPE - HPV 
negative: light grey; HPV16: pink; HPV18: blue; Other HR-HPV: dark grey; Unknown: white. DISEASE 
SEVERITY I & HPV STATUS - LSIL/Normal HPV negative: light grey; LSIL/Normal HPV positive: dark 
grey; HSIL/HPV positive: blue; Cancer: pink; unknown/other: white. KEY - ASCUS: atypical squamous cells 
of undetermined significance; CST: community state type; HPV: Human Papillomavirus; HR-HPV: high-risk 
HPV; HSIL: High-grade squamous intra-epithelial lesion; ICC: invasive cervical cancer; LSIL: Low-grade 
squamous intra-epithelial lesion.
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CST I L. 
crispatus n/N 
(%)
CST II L. 
gasseri n/N 
(%)
CST III L. 
iners n/N (%)
CST IV Mixed 
n/N (%)
CST V L. 
jensenii n/N 
(%)
TOTAL n/N 
(%)
DISEASE SEVERITY (A)
 Normal 10/20 (50) 0/20 (0) 8/20 (40) 2/20 (10) 0/20 (0) 20/20 (100)
 LSIL 22/52 (42) 1/52 (2) 12/52 (23) 11/52 (21) 6/52 (12) 52/52 (100)
 HSIL 37/92 (40) 3/92 (3) 27/92 (29) 25/92 (27) 0/92 (0) 92/92 (100)
 Cancer 1/5 (20) 1/5 (20) 0/5 (0) 2/5 (40) 1/5 (20) 5/55 (100)
 Total 70/169 (41) 5/169 (3) 47/169 (28) 40/169 (24) 7/169 (4) 169/169 (100)
 P value1 0.30 0.12 0.38 0.06 0.47 –
 Q value1 0.47 0.46 0.47 0.32 0.47 –
DISEASE SEVERITY (B) (ASCUS/LSIL separate)2
 Normal 10/20 (50) 0/20 (0) 8/20 (40) 2/20 (10) 0/20 (0) 20/20 (100)
 ASCUS 16/26 (62) 0/26 (0) 4/26 (15) 5/26 (19) 1/26 (4) 26/26 (100)
 LSIL 6/26 (23) 1/26 (4) 8/26 (31) 6/26 (23) 5/26 (19) 26/26 (100)
 HSIL 37/92 (40) 3/92 (3) 27/92 (29) 25/92 (27) 0/92 (0) 92/92 (100)
 Cancer 1/5 (20) 1/5 (20) 0/5 (0) 2/5 (40) 1/5 (20) 5/5 (100)
 Total 70/169 (41) 5/169 (3) 47/169 (28) 40/169 (24) 7/169 (4) 169/169 (100)
 P value1 0.10 0.11 0.65 0.06 0.87 –
 Q value1 0.33 0.33 0.87 0.32 0.87 –
HPV STATUS
 Negative 13/24 (54) 0/24 (0) 6/24 (25) 5/24 (21) 0/24 (0) 24/24 (100)
 Positive 38/93 (41) 2/93 (2) 25/93 (27) 26/93 (28) 2/93 (2) 93/93 (100)
 Total 51/117 (44) 2/117 (2) 31/117 (26) 31/117 (26) 2/117 (2) 117/117 (100)
 P value3 0.26 1.00 1.00 0.61 1.00 –
 Q value3 1.00 1.00 1.00 1.00 1.00 –
HPV GENOTYPE
 HPV-16 13/31 (42) 1/31 (3) 8/31 (26) 9/31 (29) 0/31 (0) 31/31 (100)
 HPV-18 3/5 (60) 0/5 (0) 1/5 (20) 1/5 (20) 0/5 (0) 5/5 (100)
 Other HR-HPV subtype 12/26 (46) 1/26 (4) 7/26 (27) 5/26 (19) 1/26 (4) 26/26 (100)
 Total 28/62 (45) 2/62 (3) 16/62 (26) 15/62 (24) 1/62 (1) 62/62 (100)
 P value3 0.74 1.00 1.00 0.81 0.50 –
 Q value3 1.00 1.00 1.00 1.00 1.00 –
DISEASE SEVERITY and HPV STATUS
 Normal/LSIL, HPV neg 11/20 (55) 0/20 (0) 6/20 (30) 3/20 (15) 0/20 (0) 20/20 (100)
 Normal/LSIL, HPV pos 17/34 (50) 0/34 (0) 7/34 (21) 7/34 (21) 3/34 (8) 334/4 (100)
 HSIL, HPV pos 21/58 (36) 2/58 (3) 16/58 (28) 19/58 (33) 0/58 (0) 58/58 (100)
 Cancer 1/5 (20) 1/5 (20) 0/5 (0) 2/5 (40) 1/5 (20) 5/5 (100)
 Total 52/117 (44) 3/117 (3) 29/117 (24) 31/117 (26) 3/117 (3) 117/117 (100)
 P value1 0.08 0.05 0.69 0.15 0.57 –
 Q value1 0.34 0.24 0.69 0.46 0.69 –
Table 2.  Rates of each CST according to disease severity and HPV status/genotype – species level. 
ASCUS: atypical squamous cells of undetermined significance; CST: Community state type; CST 
I = Lactobacillus crispatus-dominant; CST II = Lactobacillus gasseri-dominant; CST III = Lactobacillus iners-
dominant, CST IV = high-diversity, Lactobacillus spp-deplete; CST V = Lactobacillus jensenii-dominant; 
HPV: Human Papilloma Virus; HPV neg: HPV negative; HPV pos: HPV positive; HR-HPV: High-risk 
Human Papilloma Virus; HSIL: High-grade Squamous intraepithelial lesion; LSIL: Low-grade squamous 
intraepithelial lesion. 1P-value & Q-value calculated using linear regression. 2ASCUS and LSIL are split 
in two separate groups. 3P-value calculated using Fishers exact test, Q-value calculated using Benjamini-
Hochberg false discovery rate (FDR) method.
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and identified Sneathia sanguinegens as a biomarker of HSIL, which has previously been shown to associate 
with HPV infection21. Two other BV-associated bacteria; Peptostreptococcus anaerobius and Anaerococcus 
tetradius were also found to be markers of HSIL in our cohort. This further suggests that specific anaerobic 
species may play a role in disease progression, rather than simply signifying presence of HPV infection.
Bacteria are increasingly appreciated as a key player in the initiation and progression of other 
malignancies including colorectal cancer23–25 where Fusobacteria has been identified as a potential 
pro-carcinogenic bacterial class25,26. Our findings show that this class, and specifically Sneathia sanguine-
gens, is discriminatory of HSIL suggesting similar mechanisms, likely involving activation of inflamma-
tory pathways, may be involved in the cervix. Approximately one third of premalignant lesions go on 
to develop invasive cervical disease, if untreated. It is possible that the women in our cohort with CST 
IV microbiomes are those at highest risk of progression to clinically significant invasive lesions, yet our 
findings only demonstrate association, not causality, between cervical pre-cancer, persistent HPV infec-
tion and the structure of the vaginal microbiota. Whilst women with BV display higher rates of HPV 
infection14,19 the virus has been shown to induce a pro-inflammatory environment to facilitate integra-
tion of viral DNA27–31. Thus HPV infection itself may adversely impact on the host’s immune defences 
and mucosal metabolism leading to aberration of vaginal microbiota, thus promoting viral persistence 
and disease progression.
Lactobacillus spp. are classically regarded as ‘protective’, yet our study supports other previous reports 
which suggest the clinical picture may be dictated by the specific species present, and that the genus 
as a whole may not be regarded as protective in its entirety. Brotman and colleagues reported that an 
L. iners dominated vaginal microbiome (CST III) was associated with HPV-infection whereas vaginal 
microbiomes dominated by L. gasseri (CST II) exhibited the most rapid clearance of HPV infection22. 
While we did not observe over-representation of CST II or III in our CIN cohorts, the reduced preva-
lence of L. iners (CST III) concurrent with increased rates of CST IV in CIN, compared to controls may 
represents a shift from L. iners (CST III) towards a CST IV type microbiome with the acquisition of 
CIN. Unlike the majority of Lactobacillus spp., L. iners does not produce H2O2, which has been shown 
Figure 3. Analysis of richness (A) and diversity indices (B&C) with attributed CSTs for the patient 
cohort. A significantly higher number of species observed in samples classified as CST IV (A) compared 
to CST I (P < 0.001) and CST III (P < 0.01). Diversity was also significantly higher in CST IV classified 
samples as assessed by the Inverse Simpson (B) and non-parametric Shannon (C) indices compared to CST 
I (P < 0.001) and CST III (P < 0.01). Kruskall-Wallis test (Dunn’s post hoc). KEY - CST: Community state 
type; Sobs: Species observed; ** = P < 0.01; *** = P < 0.001.
Figure 4. Vaginal microbiome richness and diversity indices associated with disease status (normal, 
LSIL, HSIL and cervical cancer patients). The number of species observed increased with disease severity 
with lowest richness observed in healthy controls and highest in HSIL and ICC (A). Diversity, as assessed 
by Inverse Simpson (B) and non-parametric Shannon (C) indices followed the same pattern. KEY - HSIL: 
High-grade squamous intra-epithelial lesion; ICC: invasive cervical cancer; LSIL: Low-grade squamous intra-
epithelial lesion; Sobs: Species observed; ** = P < 0.01; *** = P < 0.001.
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to have antibacterial and antiviral properties32–34. Consistent with the possibility that H2O2-producing 
Lactobacillus spp. are protective against CIN progression, we detected higher prevalence of L. jensenii 
and L. coleohominis, both H2O2-producing lactobacilli, in women with LSIL compared to HSIL, suggests 
this species may be particularly protective in preventing progression of the dysplastic and ultimately car-
cinogenic process. Furthermore Lactobacilli spp., have been shown to be cytotoxic when co-cultured with 
cervical cancer cells in vitro, but not normal cells, independent of lactic acid concentrations, highlighting 
interactions amongst cervical cells, the microbiota and the mucosal metabolic milieu35.
Environmental and hormonal factors are also known to modulate the vaginal microbiome. Smoking 
has been previously correlated to HPV persistence and CIN as well as Lactobacillus spp. depletion and 
dysbiosis36. Although women in our study with high-grade disease were more likely to be smokers, the 
differences did not reach statistical significance and no correlation between vaginal microbial composi-
tion and smoking status was identified. A sub-analysis of smokers showed that the prevalence of CST IV 
increased with disease severity indicating that a high-diversity microbiome is correlated to disease status 
rather than smoking as a potential confounder.
Future therapeutic strategies permitting the modulation of the vaginal microbiome with oral or top-
ical regimes to a Lactobacillus spp.-dominant microbiome may be able to promote HPV clearance or 
even reverse the process of tumourigenesis, reducing the morbidity resulting from these conditions and 
Figure 5. Identification of vaginal microbiota biomarkers of LSIL vs. HSIL by LEfSe analysis. (A) 
Cladogram representing taxa with different abundance according to disease severity. Size of circle is 
proportionate to abundance of taxon. (B) Histogram of the LDA scores computed for features differentially 
abundant between LSIL and HSIL disease states. Relative abundance counts of Anaerococcus tetradius (C), 
Peptostreptococcus anaerobis (D) and Sneathia sanguinegens (E), which were found to be significantly over-
represented in HSIL whereas Lactobacillus jensenii (F) was enriched in LSIL samples (Welch’s t-test). KEY 
- HSIL: High-grade squamous intra-epithelial lesion; LDA score: Linear discriminant analysis score; LSIL: 
Low-grade squamous intra-epithelial lesion.
www.nature.com/scientificreports/
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their treatments37,38. Probiotics have been used in a similar manner to reduced recurrence of BV, through 
accurate, targeted modification of the bacterial community39.
Further research is required to understand the molecular mechanisms involved in the complex role 
that bacterial communities can play in the development of cancer. An understanding of the functional 
properties of the community state types is required in order to complement what we already know about 
their structure. Further longitudinal studies are needed to investigate the changes and stability of the 
microbiome during transition from acute HPV infection, to persistent infection through to development 
of CIN and cancer.
In summary, this is the first study to correlate the structure of the vaginal microbiome with presence 
of CIN in women of reproductive age. Our findings suggest that the presence and prevalence of specific 
vaginal microbiome CSTs may be involved in the pathogenesis of CIN and cervical cancer. We have 
also identified 5 bacterial species that could help to differentiate low- and high-grade disease, and with 
further research these may improve our understanding of the role of the bacterial microenvironment in 
HPV persistence, development of CIN and progression to cancer. Although the development of HPV 
vaccines will be the main prevention strategy for this disease, its implementation in many settings can 
be challenging due to financial, cultural barriers and lack of infrastructure. Microbiome modulation with 
pre- and probiotics towards stable Lactobacillus-dominant vaginal community structure that promotes 
HPV clearance, could represent low-cost future therapeutic strategies.
Our findings may be of future clinical and therapeutic relevance and raise the clinical question as 
to whether women with a high diversity vaginal microbiome and cervical pathology should be subject 
to more intense colposcopic surveillance and/or treatment and whether the examination of the vagi-
nal microbiome could be used as a triage tool for this population. Future longitudinal studies should 
aim to elucidate the causality between HPV infection, CIN, the immune microenvironment and the 
vaginal microbiome and increase our understanding of the role that vaginal bacteria in the tumour 
microenvironment.
Methods
Study population – Inclusion and Exclusion criteria. Ethical approval was obtained from the 
National Research Ethics Service Committee London – Fulham (Approval number 13/LO/0126). All 
experiments were performed in accordance with the approved guidelines. All patients gave informed 
consent. We included pre-menopausal non-pregnant women, 18–45 years of age who attended the col-
poscopy and gynaecology clinics at Imperial College NHS Healthcare Trust. Women were included irre-
spective of their ethnicity, parity, smoking habits, phase in their cycle and use of contraception. The type 
of contraception and the time of their cycle (follicular or luteal) were documented. Women who were 
HIV or hepatitis B/C positive, with autoimmune disorders, who received antibiotics or pessaries within 
14 days of sampling, or had a previous history of cervical treatment were excluded. Detailed medical and 
gynaecological history was collected including time since last sexual intercourse and douching practices. 
Ethnicity was self-reported as Caucasian, Asian or Black. Histology was used to classify patients into 
groups. If histology was available from both punch biopsies and treatment cones, the most severe lesion 
was documented. If histology was not available as not clinically indicated (i.e. healthy controls, low-grade 
lesions under cytological surveillance), cytology was used for classification.
Sample collection and processing. A sterile, disposable speculum was inserted, without lubricant, 
and a swab was taken from the posterior vaginal fornix using a BBLTM CultureSwabTM containing liquid 
Amies (Becton Dickinson, Oxford, UK) and stored immediately at − 80 °C. Whole-Genomic bacterial 
DNA was extracted from the swabs using a QiAmp Mini DNA kit (Qiagen, Venlo, Netherlands) as pre-
viously described [12].
HPV genotyping. HPV DNA test and 16/18 genotyping was performed according to manufacturer’s 
guidelines using the Abbott RealTime High Risk (HR) HPV assay on Abbott M2000 platform; a clinically 
validated in vitro polymerase chain reaction (PCR) assay with identification of HPV-16, -18 and 12 other 
HR HPV subtypes (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68)40.
Illumina MiSeq sequencing of 16S rRNA gene amplicons. The V1-V2 hypervariable regions 
of 16S rRNA genes were amplified by PCR using a forward and reverse fusion primer as previously 
described12. Sequencing was conducted at Research and Testing Laboratory (Lubbock, TX, USA).
16S rRNA gene sequence analysis. Sequence data were analysed in Mothur using the MiSeq SOP 
Pipeline41 Sequence reads were quality checked and normalised to the lowest number of reads. Singleton 
OTUs and OTUs < 10 reads in any sample were collated into OTU_singletons and OTU_rare phylo-
types respectively, to maintain normalisation and to minimise artefacts. OTUs were defined using a 
cut off value of 97% and result data analysed using Vegan package within the R statistical package for 
assessment of microbial composition and diversity (R Development Core Team 2008). OTU taxonomies 
(from Phylum to Genus) were determined using the RDP MultiClassifier script to generate the RDP 
taxonomy42 while species level taxonomies of the OTUs were determined using the USEARCH algorithm 
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combined with the cultured representatives from the RDP database43. Alpha and beta indices were cal-
culated from these datasets with Mothur and R using the Vegan package.
Statistical analysis. Subjects were analysed in 4 different phenotype subgroups; normal, LSIL, HSIL 
and ICC. We included women with HPV changes or ASCUS in the LSIL category and further analysed 
them separately. Furthermore, we compared HR-HPV positive versus negative women, irrespective of 
the disease status and also assessed separately women positive for HPV16 versus HPV18 versus other 
high-risk (negative for HPV16 and HPV18) oncogenic subtypes. Finally, we used data from both the 
disease and HPV status and compared normal/LSIL HR-HPV negative women, normal/LSIL HR-HPV 
positive women, HSIL HR-HPV positive and ICC patients.
Analysis of statistical differences between the vaginal microbiome of patient groups was performed 
using the Statistical Analysis of Metagenomic Profiles (STAMP) package44. Data were subjected to mul-
tivariate analysis using PCA and HCA by nearest neighbour linkage with a clustering density threshold 
of 0.75.
To assess potential ascertainment bias of selected clinical characteristics with respect to four pheno-
type categories of interest, we performed fisher’s exact test for each of the following characteristics (age, 
ethnicity, parity, smoking, menstrual cycle, contraception and time since last intercourse). To analyse the 
importance of CSTs with respect to specific phenotype categories, we tested whether CSTs are signifi-
cantly over or under-represented in any category. For this purpose we created a CST indicator variable, 
whereby CST = 1 for samples that could be assigned to the given CST and CST = 0 for all other samples. 
We performed a fisher’s exact test on the corresponding contingency table. Analyses were performed 
using R and false discovery rate adjustment (Benjamin & Hochberg) was applied to correct p-values. 
P-values and q-values < 0.05 were considered significant.
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